TRIM21 and interstitial lung disease: Notably, anti-Ro-52 co-positivity has been associated with enhanced activation of type 1 interferon pathways, which promote macrophage-driven alveolar injury and progressive pulmonary fibrosis, thereby mechanistically explaining the patient's severe, treatment-resistant ILD [9].